Canaccord Genuity analyst Ed Nash downgraded DICE Therapeutics (NASDAQ: DICE) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE